Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$19.70M-$19.70MN/M vs Q2 2021 EPS Diluted-$0.09-$0.09N/M vs Q2 2021 Operating Income-$18,909,580N/M Operating Cash Flowderived-$14,334,372N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end